Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SLN with free AI briefings, catalyst countdowns, and dilution alerts.

SLN · Silence Therapeutics plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$72.1M Cash on Hand
30.7mo Cash Runway
Follow SLN by email Get an email when SLN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SLN, unsubscribe in one click. Privacy

📣 What SLN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-PKN3 siRNA Atu027 Carcinoma, Pancreatic Ductal Phase 1/2 · NCT01808638 Completed
TMPRSS6 RNAi SLN124 Polycythemia Vera Phase 1/2 · NCT05499013 Active not recruiting
Zerlasiran Cardiovascular Diseases Phase 2 · NCT05537571 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SLN holds $72.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $7M/quarter from operations, an estimated runway of 30.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 24 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SLN files for a raise →

👥 Who Owns SLN

Insiders 0% Other 5%+ holders 31.4% Institutions (96 holders) 50.8% Public and other holders 17.8%
HolderTypeShares% of sharesAs of
Richard Ian Griffiths 5%+ holder (13D) 34,543,302 18.51% 2025-06-25
Richard Griffiths 5%+ holder (13D) 14,391,498 7.71% 2026-08-12
FMR LLC Institution (13G, 5%+) 13,180,206 7.06% 2026-09-30
Tetragon Financial Group Limited 5%+ holder (13G) 9,708,153 5.20% 2026-10-05
James Ede-Golightly
Director · +228,000 options
Insider 15,000 0.01% 2025-12-14

Share count 186,609,073 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SLN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.